Tool: DupCheckTool: DupCheck

www.DupCheck.org is a web-based tool toscreen forduplicate patients in clinical trials within and across studies, sponsors and therapeutic areas. Please visit our "Tools" page for more information.


Project FlyerProject Flyer


Click here to download 
the NEWMEDS project flyer! 


ConsortiumConsortium
consortium teaser

WorkpackagesWorkpackages
 workpackages teaser

QuicklinksQuicklinks
Project Office Project Office Annual PGB and WP Leads Meetings Annual PGB and WP Leads Meetings Project Governance Project Governance Funding Mechanisms Funding Mechanisms




  Members Area
Username:
Password:



EU
IMI | The Innovative Medicines Initiative
EFPIA | European Federation of Pharmaceutical Industries and Associations

Workpackage 02

Objectives of the Workpackage

  • To provide an authoritative review, a consensus statement and a web-resource to summarize the current status of animal models of cognition.
  • To provide an agreed battery of biologically and statistically validated neuropsychological tests of cognition that provide preclinical measures of cognition in rodents analogous to those found impaired in CIAS.
  • Using this battery, define effects of experimental rodent models of schizophrenia.
  • Evaluate using the battery and selected experimental manipulations, the effects of compounds known to influence analogous cognitive parameters in man to obtain measures of predictive validity.

Workpackage Leads:

Academic Lead: Prof. Trevor Robbins, University of Cambridge, UK
EFPIA Lead: Dr. Mark Tricklebank, Eli Lilly and Co Ltd, UK

Workpackage Partners

  • H. Lundbeck A/S
  • Eli Lilly and Company Ltd
  • GlaxoSmithKline Research and Development
  • Janssen Pharmaceutica NV
  • Orion Corporation
  • Pfizer Limited
  • F Hoffmann-La Roche AG
  • Institut de Recherches Servier
  • Abbott Laboratories

Synergy between academia and industry

This project is clearly one that is best done by collaboration between academia and industry. The academic partners bring special expertise in test development and in the neural validation of the tests. The industrial partners are best positioned to add to this: (i) cross-laboratory validation (ii) providing the novel key cognitive enhancing candidates upon which the project hinges and (iii) have the capacity to deliver mass testing of selected assays and models(perturbations) for schizophrenia, including e.g. provision of suitable transgenic mouse models. The interactive aspects of this WP would ensure its synergistic aspects and its possibilities for further clinical translation. The focus on cortical-hippocampal function and dysfunction gives a behavioural dimension to the electrophysiology work and imaging work described in WP01 and WP03 and a consistent pharmacological approach across both work plans will further assist the validation and translational aspects.

WP02 - Animal models of cognitive dysfunction that relate to clinical endpoints